TP53 R273L

CI-VAR-00003802Explore in graph →NP_000537.3:p.Arg273LeuNM_000546.5:c.818G>TClinVar 376655 CIViC 918 rs28934576

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Ovarian Neoplasm1
TP53 R273L	Carboplatin + CisplatinSubstitutes	Predictive	C	Supports Resistance	—	accepted	EID2286 Ovarian cancer patients with TP53 missense mutations were refractory to platinum-based chemotherapy (66% vs. 34% in wildtype, P=0.008) and had a shorter time to disease progression (n=54, P=0.037). A … (full text at CIViC) PMID 11595686 · Reles et al., 2001 · Open in CIViC	civic
Unmapped disease2unmapped disease
TP53 R273L	(functional)	Functional	D	Supports Dominant Negative	3	submitted	EID10538 Yeast strain yIG397 was cultured to express both wild-type (WT) and mutant R273L originally identified in an oral lesion. Should the mutant be dominant-negative (DN), TP53 will not bind and transactiv…

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
376655	Pathogenic	criteria provided, multiple submitters, no conflicts	2	Ovarian neoplasm; Li-Fraumeni syndrome; Hereditary cancer-predisposing syndrome; Li-Fraumeni syndrome 1; Neoplasm; Neuroendocrine tumor of pancreas; Embryonal rhabdomyosarcoma	germline/somatic	10	May 11, 2025	clinvar